REBEC

Public trial

Cardiovascular physiotherapy in the health care unit

Date of registration: 03/23/2020 ^(mm/dd/yyyy)
Last approval date : 03/23/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of a new substance (cysteamine 5% cream) compared to the use of hydroquinone 4% cream to treat facial blemishes

Date of registration: 03/23/2020 ^(mm/dd/yyyy)
Last approval date : 03/23/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Skin cancer with spread to the parotid: evaluation of factors that worsen the clinical picture

Date of registration: 03/23/2020 ^(mm/dd/yyyy)
Last approval date : 03/23/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Evaluation of hypersensitivity after composite resin restorations in posterior teeth made by undergraduate students

Date of registration: 03/23/2020 ^(mm/dd/yyyy)
Last approval date : 03/23/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Clinical study of the influence of surface treatment on dentin before dental restorations near the gingiva

Date of registration: 03/23/2020 ^(mm/dd/yyyy)
Last approval date : 03/23/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Clinical and microbiological evaluation of the dental canal

Date of registration: 03/23/2020 ^(mm/dd/yyyy)
Last approval date : 03/23/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Use of Local Anesthetic during third molar extraction and its effect on the prevention of postoperative pain

Date of registration: 11/19/2018 ^(mm/dd/yyyy)
Last approval date : 03/23/2020 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Comparing three drugs for reducing heart rate and blood pressure during laryngoscopy and intubation

Date of registration: 03/20/2020 ^(mm/dd/yyyy)
Last approval date : 03/20/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The effects of early parenting on autism spectrum disorder

Date of registration: 03/20/2020 ^(mm/dd/yyyy)
Last approval date : 03/20/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect, safety and action of Ketotifen associated with Famotidine in the treatment of facial stains.

Date of registration: 03/20/2020 ^(mm/dd/yyyy)
Last approval date : 03/20/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The impact of mouth radiotherapy dose distribution on the occurrence and severity of radiotherapy-induced oral mucositis

Date of registration: 03/20/2020 ^(mm/dd/yyyy)
Last approval date : 03/20/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Implementation Intention to reduce salt intake on Heart Failure

Date of registration: 03/20/2020 ^(mm/dd/yyyy)
Last approval date : 03/20/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects Of Continuous Current In Shadows And Quality Of Life In Women With Primary Hyperidrosis

Date of registration: 03/19/2020 ^(mm/dd/yyyy)
Last approval date : 03/19/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Study of the Effectiveness of Oral Solutions for Intestinal Cleansing Before Colonoscopy

Date of registration: 03/19/2020 ^(mm/dd/yyyy)
Last approval date : 03/19/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Efficacy of Selegiline Chloridate in the treatment of changes Nervous due to Surgery for Corrections in the Maxilla and Mandible

Date of registration: 03/19/2020 ^(mm/dd/yyyy)
Last approval date : 03/19/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Efficacy of Duloxetine in Chronic facial pain

Date of registration: 09/03/2018 ^(mm/dd/yyyy)
Last approval date : 03/19/2020 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Effects of full body Light Therapy on the muscular performance of Rugby athletes: randomized, double-blind, crossover and placebo-controlled clinical trial

Date of registration: 03/19/2020 ^(mm/dd/yyyy)
Last approval date : 03/19/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of the effect of Oxygen Gel on Wound Healing of patients admitted to an intensive care unit

Date of registration: 03/18/2020 ^(mm/dd/yyyy)
Last approval date : 03/18/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of nicotine on the vision and cognition of nonsmokers

Date of registration: 03/18/2020 ^(mm/dd/yyyy)
Last approval date : 03/18/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The influence of physical activity for patients with liver cirrhosis

Date of registration: 03/18/2020 ^(mm/dd/yyyy)
Last approval date : 03/18/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

06/02/2026

Clinical trials for Alzheimer’s drugs omit key populations

06/02/2026 | Jenna Kurtzweil | UIC Today

https://today.uic.edu/clinical-trials-for-alzheimers-drugs-omit-key-populations/

Racial and ethnic groups most at risk for Alzheimer’s disease are underrepresented in U.S. clinical trials, according to UIC research.

Zhuoer Lin, an assistant professor in the School of Public Health, led a study analyzing patient populations in U.S. clinical trials for Alzheimer’s treatments. He found that almost half of the trials did not report on race or ethnicity at all, and of those that did, more than 90% of participants identified as white. Comparatively few patients identified as Black, Hispanic, Native American and Asian or Pacific Islander.

Such a gap limits researchers’ understanding of how new treatments affect underrepresented populations, many of whom have a higher risk, statistically, for Alzheimer’s disease than white older adults do. Compared to white older adults, Black older adults are twice as likely to develop the neurodegenerative disease. For Hispanic older adults, the risk is 1.5 times more.

“Especially in a country as diverse as the U.S., clinical trials need to represent all populations,” Lin said.

Lin and his colleagues looked at 71 clinical trials for Alzheimer’s disease treatments conducted in the U.S. between 1997 and 2023. All were Phase 3 clinical trials: the final level of drug testing before FDA approval.

The researchers scanned the trials for any reporting on participants’ race and ethnicity, including the language used to describe participants’ race and ethnicity and whether any critical discussion was included (for example, if the report acknowledged any inequities present).

Of the 36 trials that did report on participants’ race or ethnicity, that reporting…

06/02/2026

Faster approvals only half the battle: EU trials need adaptive protocols

06/01/2026 | Gareth Macdonald | BioXconomy

https://www.bioxconomy.com/clinical-and-research/faster-approvals-only-half-the-battle-eu-trials-need-adaptive-protocols-

Streamlined approvals alone won't fix Europe's clinical trial challenges, researchers say, pointing to enrollment problems and inflexible study designs.

Faster approvals only half the battle: Adaptive protocol would aid EU trials sector

Streamlined trial approvals would only solve one of the challenges firms face when testing drugs in Europe, say the authors of a study, who argue that operational issues like poor enrollment and rigid protocols are a bigger problem.

The study—published in Clinical Microbiology and Infection—shows that while initiatives like Accelerating Clinical Trials in the European Union (ACT-EU) are a positive move, there are other issues to be addressed.

“Even when hurdles in trial initiation are overcome, challenges remain: up to one-third of clinical trials are terminated prematurely, primarily due to operational issues such as poor enrolment.

“It is a serious issue when valuable public resources are used for well-designed trials addressing important research questions, only for those to fail to deliver results,” they wrote.

Adaptive trials
Flexibility, or the lack thereof, is another challenge for Europe’s trials sector, according to the authors, who suggest greater regulatory support for adaptive protocols—that evolve while the study is ongoing—would be beneficial.

“As more trials adopt flexible structures to accommodate change, this represents a paradigm shift: rather than developing a new trial for each new research question, adaptive…

06/02/2026

Decentralized Trials Are Everywhere. Nobody Agrees What They’re For.

06/02/2026 | Moe Alsumidaie | The Clinical Trial Vanguard

https://www.clinicaltrialvanguard.com/opinion/decentralized-trials-are-everywhere-nobody-agrees-what-theyre-for/

Pick up any clinical development conference agenda from the last two years and a pattern emerges: decentralized clinical trials get their own keynote slot, their own breakout session, their own pre-conference workshop. Platform vendors have multiplied. CROs have built dedicated DCT service lines. Pfizer’s public statements have credited remote elements with accelerating COVID-19 vaccine trial logistics. The FDA issued a final guidance on conducting clinical trials with decentralized elements in September 2024, lending the whole enterprise institutional gravity. By almost every surface-level measure, decentralized trials have arrived.

The data can be made to look compelling. According to research from the Tufts Center for the Study of Drug Development’s PACT Consortium, DCT-enabled trials enrolled Asian participants at a rate of 20.9% compared to 14.2% in traditional trials, and American Indian or Alaska Native participation reached 1.9% — nearly four times the 0.5% seen in conventional designs. Those numbers get cited in investor decks, regulatory submissions, and op-eds. They are real. They are also cherry-picked from trials where DCT elements were carefully selected, well-resourced, and operationally compatible with the patient population in question.

Yet underneath the momentum, there is no shared understanding of what decentralized trials are actually supposed to accomplish — and when the stakeholders who must execute them want genuinely incompatible things, the model does not quietly underperform. It collapses.

The Stakeholders Are Not Pulling the Same Direction

06/02/2026

News hype around an experimental drug in Brazil revives familiar fears

06/02/2026 | Leonardo Coelho | Lat Am Journalism Review

https://latamjournalismreview.org/articles/news-hype-around-an-experimental-drug-in-brazil-revives-familiar-fears/

As coverage of a potential spinal cord treatment draws massive interest, science journalists are warning against media excitement outpacing early clinical reality.

In March, during Women’s History Month, a lecture on women’s presence in science at the University of São Paulo drew the attention of thousands of people. Within three minutes, all tickets for a 600-seat auditorium were sold out.

The unusually high demand was driven by interest in a specific scientist speaking: Tatiana Sampaio, a researcher at the Federal University of Rio de Janeiro who is studying a new molecule –known as polylaminin– that could become a potential treatment for spinal cord injuries.

Still in the early stages of clinical trials, the experimental treatment is not yet available to the public, although patients have been attempting to secure court-ordered access to the trials even amid growing uncertainty about its effectiveness.

Since early 2026, interest in polylaminin has exploded into a coverage frenzy that walks a fine line between hope and exaggeration.

An example of exaggerated claims came from newspaper O Tempo that published the headline: “What is polylaminin, the Brazilian drug that regenerates bone marrow and reverses paraplegia.” Meanwhile, Época Negocios published an article with a more grounding title: “How polylaminin will be used to treat spinal cord injuries that cause paraplegia and tetraplegia.”

Many, however, became more and more weary with the hype. Alicia Kowaltowski, a physician and columnist at Nexo, bluntly cautioned for people…

06/02/2026

New Butantan vaccine not recommended for pregnant women, breastfeeding mothers, and postpartum women who are breastfeeding

02/06/2026 | Juan Rodriguez | Correio do Estado

https://correiodoestado.com.br/mix/nova-vacina-do-butantan-nao-e-indicada-para-gravidas-lactantes-e-puerperas-que-estejam-amamentando/

The Brazilian dengue vaccine developed by the Butantan Institute should not be administered to pregnant women, breastfeeding mothers, and postpartum women who are breastfeeding. This restriction exists because the vaccine, recently approved by the National Health Surveillance Agency (Anvisa), has not yet been tested on these groups, preventing confirmation of its safety during pregnancy and breastfeeding.

The Butantan-DV vaccine received authorization for use at the end of 2025 and became part of the National Immunization Program. Vaccination began in January 2026 through a project implemented in cities in the states of São Paulo, Minas Gerais, and Ceará. Initially, approval covered people between 12 and 59 years old.

According to health authorities, the contraindication for pregnant women follows a common practice applied to attenuated vaccines. If a pregnant woman receives the dose by mistake, the recommendation is to immediately notify the health unit responsible for the application so that the case is officially registered and monitored during prenatal care and after the baby's birth.

Butantan vaccine is not indicated for certain groups

The same guidance applies to breastfeeding women and postpartum women. In these cases, the theoretical concern is related to the possibility of transmission of the vaccine virus to the baby through breast milk. For women who have already had children but are not breastfeeding, the contraindication does not apply.

People vaccinated by mistake during pregnancy or breastfeeding should seek a health unit and also contact the Consumer…